Business Wire

CA-ARRCUS

Share
Arrcus Continues Networking Innovation Fueled by New $30M Investment

Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, today announced a significant new investment of $30 million from Prosperity7 Ventures, NVIDIA, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst. Growing investor interest in the company comes alongside Arrcus’ success with leading Fortune 500 and Global 2000 customers and will enable the company to expand platform support, accelerate growth, and continue delivering cost-effective and transformational networking solutions to customers worldwide.

As the unprecedented adoption of AI continues, there is a growing need for distributed networking to improve the efficiency of compute infrastructure spanning datacenter, 5G, edge and hybrid/multi-cloud environments across enterprise, cloud, and network operators. Arrcus’ uniquely differentiated routing and switching platform, Arrcus Connected Edge (ACE), features a distributed microservices architecture that is flexible, high-performance, scalable, fully programmable, modular, and hybrid cloud-ready. It is deployable on various form factors, including data processing units (DPUs), merchant silicon, and compute, and enables a wide range of use cases including low-latency data center networking, modern edge deployments, telco access and transport, and hybrid multi-cloud connectivity.

Arrcus’ ACE networking platform, leveraging the NVIDIA BlueField DPU, enables customers to efficiently offload, accelerate, and isolate compute-intensive networking applications like security and traffic engineering. With the advent of GenAI applications, this gives customers the ability to have high performance secure connectivity within the data center, while delivering higher utilization and power efficiency for compute-intensive workloads.

"We are thrilled to welcome NVIDIA as our latest investor and look forward to building on our collaboration. Arrcus’ leading networking software coupled with NVIDIA's AI infrastructure will help deliver maximum efficiency to customers from data centers as well as their edge and cloud computing environments," said Shekar Ayyar, Chairman and CEO of Arrcus. "We also extend our gratitude to Prosperity7, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst for their continued support and confidence in our vision."

This collaboration between NVIDIA and Arrcus can help extend AI data center architectures to distributed configurations supported by modular designs such as the NVIDIA MGX platform.

“Modern networks are evolving to address customer needs in the era of AI,” said Kevin Deierling, senior vice president of networking at NVIDIA. “We’re collaborating with Arrcus to provide high-performance, secure and cost-efficient data center networking for a variety of accelerated computing applications.”

Arrcus is garnering significant attention for its innovative networking software solutions that enable businesses to achieve substantial cost savings while improving scalability, performance, and reliability in core, edge, and multi-cloud infrastructures. Arrcus networking is ideally suited for the telecom, financial services, and industrial verticals, amongst others.

“AI is driving the need for more flexible networking to maximize the impact of high-performance compute cycles,” said Jason Hardy, CTO for AI, Hitachi Vantara. “We are pleased to see Arrcus software working across leading industry hardware platforms for distributed datacenter networking.”

“We are excited to see the new investment in Arrcus. Arrcus networking has the potential for high performance at lower cost for datacenter and carrier networks, as well as meeting the demands of infrastructure for AI and 5G,” said Adrian Drury, MD Platform Technology Liberty Global.

“Arrcus is driving an exciting disruption in networking for datacenters and AI. After leading their D round, we are now excited to join NVIDIA and other investors in continuing to support their growth and platform adoption among leading customers,” said Abhishek Shukla, Managing Director, Prosperity7 Ventures.

"Arrcus continues to push the boundaries of networking innovation with their ACE platform. Their unique approach to leveraging distributed microservices architecture and integration with leading hardware platforms enables a wide range of networking use cases from the edge to datacenters to multi-clouds, setting them apart in the industry,” said Alan Weckel, Co-Founder and Technology Analyst at 650 Group. “This new investment further validates Arrcus' vision and capability to deliver high-performance, scalable, and cost-efficient networking solutions that meet the evolving demands of AI-driven environments."

For more information please click here.

Additional Resources

About Arrcus

Arrcus is a leading provider of networking software solutions that empower businesses to achieve unparalleled scalability, performance, and reliability in their infrastructure. Arrcus is disrupting the industry with disaggregated solutions that deliver innovative, agile, and cost-effective networking, allowing enterprises to break free from traditional, monolithic systems and embrace a more flexible, efficient, and scalable approach to modern networking. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners, and top-tier VCs. The company is headquartered in San Jose, Calif. For more information, go to www.arrcus.com or follow Arrcus on LinkedIn and Twitter/X.

About Prosperity7

Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world's leading integrated energy and chemicals company. The fund's name derives from "Prosperity Well', the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally with a long-term view in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.

For more information, please visit https://www.prosperity7vc.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718299242/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye